REGISTER
A Special Drug for Alzheimer's has Arrived! Shanghai has Issued the First Prescription for It
"After comprehensive treatment, can the data of '2 to 3 years' be further extended? Can the symptoms be further improved? We hope to get a positive answer."

Today (June 26th), "MedJ" learned from the Department of Neurology at Huashan Hospital affiliated with Fudan University that the department has issued the first prescription for the new targeted drug lecanemab for Alzheimer's Disease (AD) in China, administering injections to six patients in the early stages of AD.


These six patients will undergo an 18-month treatment cycle, with lecanemab infusions administered twice a month. "This is a milestone event in the history of Alzheimer's disease treatment in our country, marking that AD has officially entered the era of precision targeted therapy from symptomatic treatment and intervention of risk factors," said Professor Yu Jintai, Deputy Director of the Department of Neurology at Huashan Hospital, to "MedJ."


Lecanemab is the first new drug for Alzheimer's Disease (AD) to be fully approved by the U.S. Food and Drug Administration (FDA) in 20 years. It is an anti-β-amyloid (Aβ) drug that works by clearing toxic Aβ proteins from the brain, thereby reversing the pathological progression of AD, slowing the clinical course, and was approved by China's National Medical Products Administration on January 9th this year. Currently, the drug has been approved for marketing in a total of four countries worldwide.


Six patients have started treatment


The first batch of six patients, aged between 55 and 75, had all previously reported symptoms of memory decline, and were subsequently further diagnosed with early-stage Alzheimer's Disease (AD) at Huashan Hospital.


"Since last year, when the news of lecanemab's approval and the possibility of its introduction into China spread, many patients have come to the outpatient clinic to inquire about related information, wanting to know when they can use the medication," Yu Jintai told "MedJ."


Mr. Xu, 68 years old, is one of the six patients in the first group to receive the medication. He began to experience mild memory decline from 2021, which initially had little impact on his daily life. However, over time, his family noticed that Mr. Xu's symptoms were gradually worsening, often unable to accurately recall events from the previous day.


In October 2023, Mr. Xu's family took him to the Memory Impairment Specialty Clinic at Huashan Hospital. After a cognitive assessment using a scale and imaging examinations, Mr. Xu was diagnosed with early-stage Alzheimer's Disease (AD).


The disease progression of the other patients was also roughly the same. In 2022, Ms. Ma, 59, began to experience unexplained memory loss. A brain magnetic resonance imaging (MRI) at the hospital revealed atrophy of the hippocampus—a crucial part of the brain responsible for memory. At that time, Yu Jintai's team treated her with cholinesterase inhibitors.


According to Yu Jintai, the occurrence and development of Alzheimer's Disease (AD) can be divided into three stages: the "preclinical stage," where pathological changes such as amyloid-beta (Aβ) and tau proteins have already occurred in the brain, but the patient shows no symptoms; the "mild cognitive impairment stage"; and the "dementia stage," which is further divided into early, middle, and late phases. The entire course from the preclinical stage to the dementia stage can exceed 20 years. However, according to epidemiological studies, the average time for AD patients to progress from the early stages of dementia to the middle and late stages, and ultimately death, is only about 5 to 6 years.


Before the advent of lecanemab, cholinesterase inhibitors and NMDA receptor antagonists were commonly used drugs in clinical practice. They are all symptomatic treatment drugs that can improve cognition to a certain extent and enhance the quality of life, but they cannot fundamentally delay or reverse the pathological progression of AD.


Lecanemab is hailed as a "milestone" new drug for AD because it is the first to apply the concepts of "targeted modulation" and "precision diagnosis and treatment" to the clinical therapy of AD patients. It selectively binds to and clears one of the core pathological hallmarks of AD—the toxic Aβ plaques in the brain.


Data from Phase III clinical trials published at the end of 2022 in the New England Journal of Medicine showed that after 18 months of treatment, the rate of decline in cognitive and memory function in the lecanemab group was reduced by 27% compared to the placebo group.


Data from a simulation model published in "Neurology and Therapy" in April 2023 showed that, compared to the sole use of cholinesterase inhibitors, the addition of lecanemab could delay the average time for AD patients to progress to a more severe stage of the disease by 2 to 3 years.


Transforming the Clinical Diagnosis and Treatment Model


The use of lecanemab has strict regulations. Since April of this year, many AD patients have consulted in the outpatient department, and Yu Jintai's team has also started the preparation work for the medication, including strict assessments in aspects such as patient selection, operational procedures for drug treatment markers, and safety guarantees.


"The first step is to have a clear pathological diagnosis," Yu Jintai told "MedJ."


The clinical heterogeneity of AD is very large, and the earlier the diagnosis, the more difficult it is. In addition to cognitive scale assessment, the diagnosis of AD also requires clear pathological confirmation through brain Aβ-PET, Tau-PET scans, or lumbar puncture cerebrospinal fluid. Yu Jintai said that due to the previous lack of a "miracle drug," if patients do not have special requirements, doctors often directly intervene in lifestyle or provide symptomatic drug treatment for patients with cognitive and memory decline.


The situation overseas is largely the same. The Globe and Mail previously reported that in Canada, doctors usually do not use PET scans or spinal punctures to diagnose AD, because in the absence of a miracle drug, confirming the presence of amyloid plaques is of little significance.


The advent of a miracle drug will fundamentally alter this situation. Meanwhile, the current clinical evidence for beta-amyloid antibodies is concentrated in the early stages of Alzheimer's Disease (AD), hence patients in the middle and late stages do not meet the criteria for drug use. Yu Jintai analyzed, "This is because, although the drug clears the toxic beta-amyloid proteins, it may no longer be able to reverse the extensive harmful downstream pathological processes that have occurred in the brains of patients in the middle and late stages."


For patients with mild symptoms of AD who are admitted to the hospital and meet preliminary drug indications, Yu Jintai's team further carried out MRI, SWI (Susceptibility Weighted Imaging) examinations, and APOE gene testing to ensure that the patients do not have ischemic or hemorrhagic foci in the brain and are not homozygous carriers of the APOEε4 gene.


It is understood that ARIA (Amyloid-Related Imaging Abnormalities), including cerebral edema (ARIA-E) and cerebral hemorrhage (ARIA-H), are common side effects of amyloid-beta antibody drugs. Patients who are homozygous for the APOEε4 allele are considered to be at a higher risk for such events. According to the package insert of lecanemab, "When deciding to initiate treatment, consider testing for APOEε4 status to inform the risk of ARIA."


"This is the first time we have used this drug after it was approved by our country's National Medical Products Administration. We must select patients according to strict standards, assess the benefit-risk ratio, reduce the risk of complications, and allow patients to benefit to the greatest extent possible," Yu Jintai told "MedJ." Among the many patients willing to take the medication, the team has initially screened about 50 people.


It is understood that after conducting treatment for the first six patients today, the team will also carry out further assessments and observations, and gradually carry out standardized treatment for the remaining patients according to specific circumstances.


It's worth mentioning that on the 10th of this month, the U.S. FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 11 to 0 in favor of the benefits of another similar drug, donanemab, for the treatment of AD outweighing the risks, recommending FDA approval. Donanemab received acceptance for its new drug application from China's National Medical Products Administration in October 2023.


A New Era of Alzheimer's Disease Treatment


According to statistics from Alzheimer's Disease International (ADI), AD currently affects about 55 million people worldwide. China is one of the countries with the highest number of AD patients globally. According to the "2022 China Alzheimer's Disease Report," there are 13 million people with mild cognitive impairment due to AD and 9.83 million AD dementia patients in the population aged 60 and above in China.


The development of new drugs for AD has long been known as a "black hole" in research and development, being one of the areas with the highest failure rates in the pharmaceutical industry. Yu Jintai believes that the breakthrough of "miracle drugs" also signifies that the diagnosis and treatment of AD have officially entered a new era of precision medicine.


Yu Jintai has nearly 20 years of clinical diagnosis, treatment, and research experience in AD. He told "MedJ" that before around 2010, there was a general lack of awareness about the prevention and treatment of AD in China. "Patients have a strong sense of stigma associated with 'senile dementia,' and many family members also don't take it seriously, thinking it's a natural manifestation of aging."


At that time, there were few specialized clinics for "memory impairment" in hospitals, and diagnosis and treatment were generally carried out in routine neurology outpatient clinics. "AD patients may have related symptoms such as sleep disorders and abnormal mental behaviors. Doctors usually prescribe some medications for sleep, mood, or mental conditions as needed. Due to the lack of effective treatment methods, many patients do not request a clear diagnosis either."


With the advancement of technology, diagnostic and treatment plans have been continuously evolving. "In the past, we usually first assessed whether the patient had 'dementia' and then determined the type of dementia based on specific manifestations, intervening symptomatically and etiologically," said Yu Jintai. "Now, even if a patient has not shown any symptoms, we can make an early and precise diagnosis through biological markers such as PET scans or cerebrospinal fluid, which has moved the frontier of precise prevention and treatment of AD forward."


The foundation for realizing the value of "moving the disease diagnosis threshold forward" is to have a clear intervention method. In 2015, Yu Jintai's team published a significant study in the American "Prevention Magazine," which for the first time proposed the nine major risk factors that contribute to the development of Alzheimer's Disease (AD).


Based on this research, in 2020, Yu Jintai's team led the development of the world's first international guidelines for evidence-based prevention of AD, which suggests that at least 40% of the onset of Alzheimer's disease can be prevented through a 21-pronged approach that includes control of vascular risk factors and management of weight, blood pressure, sleep, exercise, and diet. In the same year, The Lancet published a similar report, led by 28 of the world's top dementia research experts, suggesting 12 risk factors that can delay or prevent the onset of dementia.


With the means of intervention, the public's awareness of early diagnosis has also increased. In recent years, Yu Jintai often encounters young patients in their 30s and 40s in outpatient clinics who have only mild memory loss, but because of a family history of AD and risk factors for AD, they hope to undergo an early pathologic examination to assess the risk of developing the disease in the future and to carry out timely intervention.


For patients who have entered the “mild cognitive impairment stage”, “including cognitive function training, aerobic exercise, transcranial magnetic stimulation therapy, etc., AD non-pharmacological interventions are also becoming more abundant.” Yu Jintai said.


The introduction of beta amyloid antibody drugs further completes the “map”. “It is equivalent to the current targeted preventive and therapeutic means, which has been realized throughout the period of mild cognitive impairment in AD and the early stage of dementia.” It is understood that with lecanemab in use, Yu Jintai's team will also open a new study.


“The predictive modeling of lecanemab's clinical data suggests a 2- to 3-year delay in disease progression, but AD is a complex disease, and clinical practice can be characterized by a 'cocktail of therapies' that improves pathology in the brain with targeted agents on the one hand, and symptomatic treatment to alleviate symptoms on the other hand, while combined with continuous lifestyle intervention, risk factor management, etc.”


“Can the figure of '2 to 3 years' be extended further after comprehensive treatment? Is it possible to improve the symptoms further? We hope to get a positive answer.” Yu Jintai said.


This is just the beginning


On July 17, 2023, JAMA published an editorial, “A New Era in Alzheimer's Disease Treatment,” stating that while there is no “cure,” the emergence of new targeted drugs similar to the beta-amyloid antibody drugs will ultimately change the research and clinical landscape of AD.


“Accurate early diagnosis of AD, personalized assessment of benefit-risk ratios, and emphasis on disease management throughout the course of AD will follow with increased emphasis.” The editorial states.


Both lecanemab and donanemab are currently being tested in “preclinical” AD risk groups to determine if they can further advance the therapeutic window to prevent future cognitive decline and stop AD altogether. The trials are expected to continue until 2027.


A paradigm shift in AD management from tertiary to primary prevention would help reduce the associated disease burden. In the field of vaccines, although no breakthroughs have yet been achieved, the academic community has also been exploring the use of active or passive immunotherapy to prevent the development of AD.


Similar to antibody drugs, trials of AD vaccines continue to focus on patients in the early stages of the disease, and in June 2023, the U.S. FDA granted breakthrough therapy designation to the “ACI-24.060 vaccine” for anti-Aβ immunotherapy. A systematic evaluation published in the same issue of the open-access journal Cureus noted that most of the 16 clinical trials of seven different types of AD vaccines reported favorable safety and immunogenicity results, but that sufficiently robust phase III data are needed to demonstrate ultimate efficacy.


In terms of diagnosis, blood testing has gradually become popular in the field of AD research in recent years. At the beginning of this year, Yu Jintai's team and Prof. Yip Yuk-yu's team at the Hong Kong University of Science and Technology published research results one after another, and it is expected that the diagnosis of AD can be advanced to 15 years before the onset of the disease through blood biomarker testing.


Compared to the current relatively cumbersome or expensive cerebrospinal fluid tests and PET scans, AD blood tests offer the highly imaginative prospect of efficiently and conveniently detecting AD risk, further expanding the population for early screening, and even incorporating them into routine medical checkups, with a view to intervening for medical intervention at the earliest possible stage.


Yu Jintai told “MedJ” that there are clear therapeutic thresholds for hyperglycemia and hypercholesterolemia, and that “the challenge for AD treatment is to find a stable and accurate blood marker that reflects the pathological changes in the brain, and to define the thresholds for the corresponding markers for early treatment.” ”


As the only potent drug for AD, lecanemab costs up to $180,000 a year to administer, and there is still a lot of room for exploration on how to make it affordable and accessible to more patients. At the same time, Yu Jintai believes there is every hope that AD will be overcome in the future. “The approval of the new drug is just the beginning, and with the theoretical breakthroughs in basic disease research, precision diagnosis, and targeted drug development, there are still infinite possibilities in this field.”




0
0
Loading